Cynata Therapeutics Ltd
51S
Company Profile
Business description
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.
Contact
100 Cubitt Street
Level 3
CremorneVIC3121
AUST: +61 370676940
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
2
Stocks News & Analysis
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
stocks
Here’s 3 Top Rated ASX shares for 2026
As we start the new year, let’s take a closer look at three compelling opportunities on the ASX
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.50 | 7.00 | 0.08% |
| CAC 40 | 8,243.47 | 6.04 | 0.07% |
| DAX 40 | 25,080.10 | 42.16 | -0.17% |
| Dow JONES (US) | 49,336.64 | 340.56 | 0.70% |
| FTSE 100 | 10,021.34 | 26.87 | -0.27% |
| HKSE | 26,149.31 | 561.14 | -2.10% |
| NASDAQ | 23,462.09 | 85.08 | -0.36% |
| Nikkei 225 | 51,117.26 | 1,400.82 | -2.67% |
| NZX 50 Index | 13,716.86 | 1.84 | 0.01% |
| S&P 500 | 6,924.66 | 3.73 | 0.05% |
| S&P/ASX 200 | 8,720.80 | 2.70 | -0.03% |
| SSE Composite Index | 4,082.98 | 2.79 | -0.07% |